How Pfizer and Ada Health’s AI-assisted app aims to help those suffering from COVID – AI News Update

How Pfizer and Ada Health’s AI-assisted app aims to help those suffering from COVID

Discover all the Smart Security Summit on-demand sessions here.

Getting COVID-19 is no fun, but the key to getting better faster has a lot to do with getting treatment sooner.

digital health provider Ada Health today announced its partnership with drugmaker Pfizer on a artificial intelligence (AI)-assisted app to help people who are experiencing the onset of COVID symptoms get the right treatment as soon as possible. The new COVID-19 Care Journey app, operated by Ada Health, in partnership with Pfizer, can help individuals determine what steps to take to help address symptoms. With the right conditions, it can also be used to help direct users get the right antiviral medication to reduce the impact of symptoms and speed up recovery.

The COVID-19 Care Journey will be available as a standalone service, in addition to being part of the Ada app, which is an AI-powered mobile app that the company says has been downloaded over 12 million times. . The Ada app uses AI to help with initial triage and diagnosis of potential health issues.

“We’re practically helping our users find out what health issues they might have and then how they can address them in the next step,” Daniel Nathrath, CEO and co-founder of Ada, told VentureBeat. “We’re now taking Ada’s usefulness a step further, and rather than telling users what they might have and what they can do, we’re focusing on providing the solution to them as part of a journey. seamless end-to-end care.”


On-Demand Smart Security Summit

Learn about the essential role of AI and ML in cybersecurity and industry-specific case studies. Watch the on-demand sessions today.

look here

How the Care Journey service works

Nathrath explained that what the service does is help determine if someone is eligible for antiviral treatment for COVID.

“COVID antiviral drugs are now available and they’re quite effective, but they’re not necessarily reaching the people who need them most,” he said. “It’s partly because people don’t really know whether they’re eligible or not and sometimes even doctors don’t really know.”

The COVID-19 care pathway provides a specific eligibility questionnaire to help determine if a user meets the criteria set by the US Centers for Disease Control and Prevention (CDC) for the use of COVID antiviral medications. For those who are eligible, the service can connect the user with a telehealth physician who can then prescribe the medication themselves.

While the service is being developed in partnership with Pfizer, which makes the antiviral drug Paxlovid, Nathrath stressed that doctors are free to prescribe any appropriate antiviral drug.

After a doctor has issued a prescription, the Care Journey service can also help ensure that the medicine gets to the patient as quickly as possible, which is crucial when dealing with antiviral treatments as they need to be taken in the first few days to be effective.

“The idea here is really to make the whole journey a lot more painless for the patient,” Nathrath said. “If you have an infectious disease, the last thing you want – and the last thing anyone wants – is for you to sit in the waiting room of your family doctor’s office and pass on the disease. infection to 10 other people.”

The AI ​​doctor will see you now

The heart of the Ada application is based on an AI system that the company has developed over the past twelve years.

Nathrath explained that his company’s AI trained on a very large curated medical knowledge base. It’s an effort he says involved hundreds of doctors to fine-tune and get the right results.

As part of the AI ​​development process, Ada Health developed its own domain-specific programming language. With this language, he is able to potentially identify several thousand different diseases and tens of thousands of symptoms. The information is all collected as structured data and behind it is a probabilistic reasoning engine.

A probabilistic engine works differently from large language model (LLM) approach that has become popular in recent years with AI.

“We consciously decided to take the approach that we have taken, because it is more explainable, it’s not a black box,” Nathrath said. “So it’s a much more guided conversation than you would have with something like ChatGPT and for that specific use case, we think that’s actually the best fit.”

VentureBeat’s mission is to be a digital public square for technical decision makers to learn about transformative enterprise technology and conduct transactions. Discover our Briefings.

How Pfizer and Ada Health’s AI-assisted app aims to help those suffering from COVID

Source link